CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion

Laboratory Investigation

Volumn 84, Issue 12, 2004, Pages 1666-1676

  Singh, Shailesh ^a   Singh, Udai P ^a   Grizzle, William E ^b   Lillard Jr , James W ^a,b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemokine; Metalloproteinase; Metastasis; SDF 1; Stromal cell derived factor 1

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR4 ANTIBODY; COLLAGENASE; COLLAGENASE 1; COLLAGENASE 3; MATRIX METALLOPROTEINASE 14; RECEPTOR ANTIBODY; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; EPITHELIUM CELL; EVALUATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MODULATION; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CXC; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METALLOPROTEASES; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 10044284415     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700181     Document Type: Article

References (62)

1. Fidler IJ. Critical determinants of metastasis. Sem Cancer Biol 2002;12:89-96.
2. Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metast Rev 1993;12:325-343.
3. Wang JM, Deng X, Gong W, et al. Chemokine and their role in tumor growth and metastasis. J Immunol Methods 1998;220:1-17.
4. Yeatman TJ, Nicolson GL. Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. Semin Surg Oncol 1993;9:256-263.
5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
6. Butcher EC, Willima M, Youngman K, et al. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-253.
7. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
8. Hulboy DL, Rudolph LA, Matrisian M. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 1997;3:27-45.
9. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 1993;9:541-573.
10. Tiachman RS, Cooper C, Keller ET, et al. Use of stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
11. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Internal Med 1993;118:793-803.
12. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21:337-344.
13. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379.
14. Sehgal A, Keener C, Boynton AL, et al. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 1998;69:99-104.
15. Slanicka KM, Nissen C, Manz CY, et al. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow. Exp Hematol 1998;26:356-373.
16. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94:3658-3667.
17. Mohle R, Failenschmid C, Bautz F, et al. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999;13:1954-1959.
18. Gupta SK, Pillarisetti K, Lysko PG. Modulation of CXCR4 expression and SDF-1alpha functional activity during differentiation of human monocytes and macrophages. J Leuk Biol 1999;66:135-143.
19. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor. Clin Cancer Res 2000;6:3530-3535.
20. Arai J, Yasukawa M, Yakushijin Y, et al. Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol 2000;64:323-332.
21. Mohle R, Schittenhelm M, Failenschmid C, et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000;110:563-572.
22. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-4757.
23. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-473.
24. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 1998;50:97-116.
25. Cockett MI, Murphy G, Birch ML, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998;63:295-313.
26. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-462.
27. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261.
28. Wirl G, Frick J. Collagenase - a marker enzyme in human bladder cancer? Urol Res 1979;7:103-108.
29. Durkan GC, Nutt JE, Tajjayabun PH, et al. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001;7:3450-3456.
30. Kanbe K, Takagishi K, Chen Q. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. Arthritis Rheum 2002;46:130-137.
31. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
32. Ponomaryov T, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000;106:1331-1339.
33. Gohji K, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998;79:96-101.
34. Raab G, Moses MA, Adam RM, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. J Cell Biochem 1998;69:143-153.
35. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-1399.
36. Sehgal G, Hua J, Bernhard EJ, et al. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998;152:591-596.
37. Janowska-Wieczorek A, Marquez LA, Dobrowsky A, et al. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol 2000;28:1274-1285.
38. Klier CM, Nelson EL, Cohen CD, et al. Chemokine-induced secretion of gelatinase B in primary human monocytes. Biol Chem 2001;382:1405-1410.
39. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res 2003;44(Suppl 1):79-84.
40. Lane WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000;96:4152-4159.
41. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Stromal-derived factor I and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000;96:4142-4151.
42. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002;100:2597-2606.
43. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
44. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-608.
45. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
46. Birkedal-Hansen B, Pavelic ZP, Gulckman JL, et al. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis 2000;6:376-382.
47. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-65.
48. Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216-1222.
49. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439-442.
50. Stanton H, Gavrilovic J, Atkinson SJ, et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998;111:2789-2798.
51. Nomura H, Sato H, Seiki M, et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55:3263-3266.
52. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-4110.
53. Nagakawa O, Murakami K, Yamaura T, et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173-179.
54. Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-lalpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004;64:2534-2543.
55. Fuchs S, Skwara A, Bloch M, et al. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthritis Cartilage 2004;12:409-418.
56. Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43:801-811.
57. Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276:45098-45105.
58. Laakko T, Juliano RL. Adhesion regulation of stromal cell-derived factor-1 activation of ERK in lymphocytes by phosphatases. J Biol Chem 2003;278:31621-31628.
59. Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998;273:23169-23175.
60. Yonezawa A, Hori T, Sakaida H, et al. SDF-1 has costimulatory effects on human T cells: possible involvement of MAPK (ERK2) activation. Microbiol Immunol 2000;44:135-141.
61. Lee Y, Gotoh A, Kwon HJ, et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 2002;99:4307-4317.
62. Vaalamo M, Mattila L, Johansson N, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997;109:96-101.